NEWS
Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial Radiation Therapy
BOCA RATON, Fla., Dec. 6, 2018 /PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announced today positive results of a multicenter case series of patients treated with the SRT-100™ following complete surgical keloidectomy. Of the 297 patients treated post-operatively with superficial radiation, there were only nine cases of observed clinical keloid recurrences, or a recurrence rate of 3%. The results of the study were published in the November issue of SKIN, The Journal of Cutaneous Medicine.
Read the full press release here.
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
95%+ cure rates that rival surgery
No anesthesia, cutting, bleeding, stitching or pain
No downtime or lifestyle restrictions
Super cosmesis, no unsightly scarring
No need for post-treatment reconstructive surgeries